Balaxi Healthcare Dominicana SRL Pharmaceutical Import Profile — Dominican Republic (DGFT 2022–2026)

Name: Balaxi Healthcare Dominicana SRL Pharmaceutical Import Records from India — 3 Products, $1.1M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Balaxi Healthcare Dominicana SRL — Pharmaceutical Importer Profile (2026) | 3 Products, $1.1M Trade | TransData Nexus

Balaxi Healthcare Dominicana SRL

Pharmaceutical Importer · Dominican Republic · Antifungals Focus · $1.1M Total Trade · DGFT Verified

Balaxi Healthcare Dominicana SRL is a pharmaceutical importer based in Dominican Republic with a total trade value of $1.1M across 3 products in 3 therapeutic categories. Based on 57 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Balaxi Healthcare Dominicana SRL sources from 2 verified Indian suppliers, with Balaxi Pharmaceuticals Limited accounting for 78.9% of imports.

Balaxi Healthcare Dominicana SRL — Import Portfolio & Supplier Network

Balaxi Healthcare Dominicana SRL import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Balaxi Healthcare Dominicana SRL?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Balaxi Pharmaceuticals Limited	$5.2M	675	78.9%
Balaxi Ventures Limited	$1.4M	145	21.1%

Balaxi Healthcare Dominicana SRL sources from 2 verified Indian suppliers across 559 distinct formulations. Total import value: $6.6M across 820 shipments.

What Formulations Does Balaxi Healthcare Dominicana SRL Import?

Formulation	Value	Ships
Ciprofloxacin 500 MG coated tablets	$215.2K	11
Cefalexin 500 MG capsules	$210.2K	6
Diclopara tablets (gstin-02aaccb8447r2z8	$126.1K	5
Diclopara tablets gstin-23aajcs0547g1zj	$125.9K	3
Azithromycin 500 MG coated tablets	$112.5K	6
Ranitidine 300 MG coated tablets	$99.6K	5
Amoxy plus 312.5 MG/5 ML oral	$90.9K	6
O.r.s 27.9 g (gstin-23aajcs0547g1zj/tax	$80.6K	3
Metronidazole intravenous infusion 500	$66.7K	5
Vitamin b complex solution injectable	$65.6K	5
Diclopara tablets gstin-23aajcs0547g1zj/tax document no.a3227/23-24 packing-10x10 10000 tabs/ctn - 10x10x10x10	$65.1K	2
Nanvit-c chewable tablets	$61.0K	3
Clarithromycin 500 MG tablets	$61.0K	7
Ampicillin 1000 MG coated tablets	$50.0K	1
Cefalexin 500 MG capsules	$50.0K	1

Balaxi Healthcare Dominicana SRL imports 559 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Nystatin	Antifungals	$699.4K	24	1.3%	9
2	Ranitidine	Gastrointestinal	$274.6K	20	2.2%	8
3	Captopril	Cardiovascular	$89.5K	13	0.7%	9

Balaxi Healthcare Dominicana SRL imports 3 pharmaceutical products across 3 categories into Dominican Republic totaling $1.1M.

Balaxi Healthcare Dominicana SRL — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Balaxi Healthcare Dominicana SRL is a pharmaceutical trading company headquartered in Santo Domingo, Dominican Republic. The company specializes in the importation and distribution of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Their portfolio encompasses a diverse range of products across various therapeutic categories, reflecting a commitment to enhancing healthcare accessibility and quality within the Dominican market.

The company's operations are strategically aligned with its parent entities, Balaxi Pharmaceuticals Limited and Balaxi Ventures Limited, both based in India. These affiliations underscore a robust supply chain and a focus on sourcing high-quality pharmaceutical products. Balaxi Healthcare Dominicana SRL plays a pivotal role in the Dominican Republic's pharmaceutical distribution network, serving as a key importer and distributor that bridges international pharmaceutical manufacturers with local healthcare providers.

2Distribution Network

Balaxi Healthcare Dominicana SRL's distribution network is centralized at its headquarters located at Calle Jose de Jesus Ravelo No. 73, Villa Juana, Santo Domingo, Dominican Republic. This strategic location facilitates efficient logistics and accessibility to major urban centers across the country. While specific details regarding additional warehouse locations and logistics capabilities are not publicly disclosed, the company's centralized operations suggest a streamlined distribution process within the Dominican Republic.

The company's geographic coverage primarily spans the Dominican Republic, with potential export activities to neighboring countries. However, detailed information regarding international distribution beyond the Dominican Republic is not readily available. Balaxi Healthcare Dominicana SRL's logistics operations are likely designed to ensure timely and efficient delivery of pharmaceutical products to meet the demands of the local healthcare sector.

3Industry Role

In the Dominican Republic's pharmaceutical supply chain, Balaxi Healthcare Dominicana SRL functions as a primary wholesaler and importer. By sourcing finished pharmaceutical formulations from its parent companies in India, the firm acts as a conduit, facilitating the entry of these products into the Dominican market. This role is crucial in ensuring the availability of a diverse range of pharmaceutical products to meet the healthcare needs of the population.

The company's operations are characterized by a focus on importing finished pharmaceutical products, indicating a strategic emphasis on providing ready-to-use medications to the local market. This approach aligns with the regulatory requirements of the Dominican Republic, which necessitate that imported pharmaceutical products possess a Sanitary Register issued by the Ministry of Public Health.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Balaxi Healthcare Dominicana SRL

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Balaxi Healthcare Dominicana SRL demonstrates a high degree of supplier concentration, with 78.9% of its imports sourced from Balaxi Pharmaceuticals Limited and 21.1% from Balaxi Ventures Limited. This sourcing strategy indicates a strategic choice to maintain strong, stable relationships with a select group of suppliers, potentially ensuring consistent product quality and supply reliability.

The company's import data reveals a consistent pattern of shipments from these two suppliers, suggesting a stable and ongoing partnership. However, the lack of diversification in supplier relationships may pose risks, such as vulnerability to supply chain disruptions or changes in supplier dynamics. Balaxi Healthcare Dominicana SRL's reliance on a limited number of suppliers underscores the importance of robust contingency planning and risk management strategies to mitigate potential disruptions.

2Supply Chain Resilience

Balaxi Healthcare Dominicana SRL's supply chain resilience is closely tied to its reliance on two primary Indian suppliers: Balaxi Pharmaceuticals Limited and Balaxi Ventures Limited. While this focused supplier base may streamline operations, it also presents challenges in terms of supply chain diversification. The company does not publicly disclose information regarding backup suppliers or alternative sourcing strategies, which could be critical in mitigating risks associated with supply chain disruptions.

Importing Pharmaceuticals into Dominican Republic — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Dominican Republic

1Regulatory Authority & Framework

The Dominican Republic's pharmaceutical sector is regulated by the Ministry of Public Health and Social Assistance (SESPAS), which oversees the General Directorate of Medicines, Food, and Health Products (DIGEMAPS). This body is responsible for ensuring the safety, efficacy, and quality of pharmaceutical products entering the country.

Key legislation governing pharmaceutical imports includes the General Law on Health and Regulation No. 246-06 on Medicines. These regulations stipulate that pharmaceutical products, including finished formulations, must obtain a Sanitary Register from SESPAS before being marketed in the Dominican Republic. The Sanitary Register is valid for five years and is a prerequisite for the importation and sale of pharmaceutical products.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in the Dominican Republic are stringent. Importers must secure a Sanitary Register from the Ministry of Public Health for each product they intend to import. This process involves submitting comprehensive documentation, including proof of compliance with Good Manufacturing Practices (GMP) standards. GMP certification from recognized authorities, such as the European Union (EU), World Health Organization (WHO), or Pharmaceutical Inspection Co-operation Scheme (PIC/S), is typically required to ensure product quality and safety.

Balaxi Healthcare Dominicana SRL — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Balaxi Healthcare Dominicana SRL's product strategy focuses on importing finished pharmaceutical formulations across three therapeutic categories: antifungals, gastrointestinal medications, and cardiovascular drugs. This strategic selection aligns with the company's import data, which indicates that antifungals constitute 65.8% of imports, gastrointestinal medications 25.8%, and cardiovascular drugs 8.4%.

The emphasis on antifungals suggests a response to prevalent fungal infections within the Dominican Republic, indicating a significant market demand for such treatments. The inclusion of gastrointestinal and cardiovascular products reflects a comprehensive approach to addressing common health concerns, ensuring that the company meets a broad spectrum of patient needs.

2Sourcing Profile

Balaxi Healthcare Dominicana SRL's sourcing strategy is heavily centered on generic drug formulations, primarily imported from its parent companies in India. This focus allows the company to offer cost-effective pharmaceutical solutions while maintaining a diverse product portfolio. The importation of 559 unique formulations underscores a commitment to providing a wide range of therapeutic options to the Dominican market.

India's established reputation for producing high-quality generic pharmaceuticals positions it as a strategic partner for Balaxi Healthcare Dominicana SRL. The company's sourcing profile indicates a reliance on these partnerships to meet the regulatory standards of the Dominican Republic and fulfill market demands.

Frequently Asked Questions — Balaxi Healthcare Dominicana SRL

What products does Balaxi Healthcare Dominicana SRL import from India?

Balaxi Healthcare Dominicana SRL imports 3 pharmaceutical products across 3 categories. Top imports: Nystatin ($699.4K), Ranitidine ($274.6K), Captopril ($89.5K).

Who supplies pharmaceuticals to Balaxi Healthcare Dominicana SRL from India?

Balaxi Healthcare Dominicana SRL sources from 2 verified Indian suppliers. The primary supplier is Balaxi Pharmaceuticals Limited (78.9% of imports, $5.2M).

What is Balaxi Healthcare Dominicana SRL's total pharmaceutical import value?

Balaxi Healthcare Dominicana SRL's total pharmaceutical import value from India is $1.1M, based on 57 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Balaxi Healthcare Dominicana SRL focus on?

Balaxi Healthcare Dominicana SRL imports across 3 categories. The largest: Antifungals (65.8%), Gastrointestinal (25.8%), Cardiovascular (8.4%).

Get Full Balaxi Healthcare Dominicana SRL Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.